Description

High-content screening (HCS, also known as high-content analysis, or HCA) is an approach to cell biology that combines automated imaging and quantitative data analysis in a high-throughput format suitable for large-scale applications such as drug discovery and systems biology. Today high-content screening is established in a far broader area of the life science space as an unbiased imaging method to assess cellular function. The global high content screening market is set to grow by US$ 1.04 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.4% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for high content screening. The global high content screening market is segmented on the basis of product, application, end user, and region. By product, it is categorized into instruments, consumables, software, and services. The instruments segment held the largest market share in 2020. By application, the high content screening market is divided into drug discovery, oncology, compound profiling, molecular diagnosis, toxicity studies, and neuroscience. Based on end user, the high content screening market is divided into pharmaceutical & biotechnology companies, academics, and laboratories.

The report has profiled some of the key players of the market such as Becton Dickinson and Company, Biotek Instruments Inc., Danaher Corporation (Molecular Devices LLC), Genedata AG, PerkinElmer Inc., Tecan Group Ltd., Thermo Fisher Scientific Inc., Thorlabs Inc., Yokogawa Electric Corporation.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the high content screening market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: instruments, consumables, software, and services
Application: drug discovery, oncology, compound profiling, molecular diagnosis, toxicity studies, and neuroscience
End user: pharmaceutical & biotechnology companies, academics, and laboratories
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global high content screening market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global high content screening market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. High Content Screening Market by Product
4.1 Instruments
4.2 Consumables
4.3 Software
4.4 Services
5. High Content Screening Market by Application
5.1 Drug Discovery
5.2 Oncology
5.3 Compound Profiling
5.4 Molecular Diagnosis
5.5 Toxicity Studies
5.6 Neuroscience
6. High Content Screening Market by End User
6.1 Pharmaceutical & Biotechnology Companies
6.2 Academics
6.3 Laboratories
7. High Content Screening Market by Region
7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 Becton, Dickinson and Company
8.2 Biotek Instruments, Inc.
8.3 Danaher Corporation (Molecular Devices, LLC)
8.4 Genedata AG
8.5 PerkinElmer, Inc.
8.6 Tecan Group Ltd.
8.7 Thermo Fisher Scientific Inc.
8.8 Thorlabs, Inc.
8.9 Yokogawa Electric Corporation
9. Appendix
9.1 About StrategyHelix
9.2 Disclaimer